Today's Daily Dose brings you news about Kamada's proposed phase III trial for inhaled Alpha-1 Antitrypsin (AAT) therapy; cost-effectiveness of EnteroMedics' vBloc therapy for obesity; Bristol-Myers and Daiichi Sankyo's partnership; Nasdaq's warning for Biostar Pharma; La Jolla's and Roche's upcoming regulatory catalysts, and approval of Tandem Diabetes' sensor-augmented insulin pump.
from RTT - Biotech http://ift.tt/2vnIHBy
via IFTTT
No comments:
Post a Comment